330:
validated in an anticoagulated trial cohort of 7329 people with AF - in this study, the HAS-BLED score offered some improvement in predictive capability for bleeding risk over previously published bleeding risk assessment schemas and was simpler to apply. With the likely availability of new oral anticoagulants that avoid the limitations of warfarin (and may even be safer), more widespread use of oral anticoagulation therapy for stroke prevention in AF is likely.
329:
2020 ESC guidelines on atrial fibrillation recommend assessment of bleeding risk in AF using the HAS-BLED bleeding risk schema as a simple, easy calculation, whereby a score of ≥3 indicates "high risk" and some caution and regular review of the patient is needed. The HAS-BLED score has also been
756:
Camm, A. J.; Lip, G. Y. H.; De
Caterina, R.; Savelieva, I.; Atar, D.; Hohnloser, S. H.; Hindricks, G.; Kirchhof, P.; Bax, J. J.; Baumgartner, H.; Ceconi, C.; Dean, V.; Deaton, C.; Fagard, R.; Funck-Brentano, C.; Hasdai, D.; Hoes, A.; Kirchhof, P.; Knuuti, J.; Kolh, P.; McDonagh, T.; Moulin, C.;
463:"Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study"
625:
Hindricks, Gerhard; Potpara, Tatjana; Dagres, Nikolaos; Arbelo, Elena; Bax, Jeroen J.; Blomström-Lundqvist, Carina; Boriani, Giuseppe; Castella, Manuel; Dan, Gheorghe-Andrei; Dilaveris, Polychronis E.; Fauchier, Laurent (2020-08-29).
333:
While their use is recommended in clinical practice guidelines, they are only moderately effective in predicting bleeding risk and don't perform well in predicting hemorrhagic stroke. Bleeding risk may be increased in patients on
510:
Fox, Keith A. A.; Lucas, Joseph E.; Pieper, Karen S.; Bassand, Jean-Pierre; Camm, A. John; Fitzmaurice, David A.; Goldhaber, Samuel Z.; Goto, Shinya; Haas, Sylvia; Hacke, Werner; Kayani, Gloria (21 December 2017).
720:
Lip, Gregory Y.H.; Frison, Lars; Halperin, Jonathan L.; Lane, Deirdre A. (2011). "Comparative
Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation".
366:
Pisters, Ron; Lane, D. A.; Nieuwlaat, R; De Vos, C. B.; Crijns, H. J.; Lip, G. Y. (2010). "A Novel User-Friendly Score (HAS-BLED) to Assess 1-Year Risk of Major
Bleeding in Patients with Atrial Fibrillation".
513:"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation"
326:
and HAS-BLED showed superior performance of the HAS-BLED score compared to the other two. Mixed evidence exist on the comparison between GARFIELD-AF bleeding score over the HAS-BLED.
628:"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)"
759:"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation"
568:
Proietti, Marco; Rivera-Caravaca, José Miguel; Esteve-Pastor, María Asunción; Romiti, Giulio
Francesco; Marin, Francísco; Lip, Gregory Y. H. (18 September 2018).
847:
Elliott, Meghan J.; Zimmerman, Deborah; Holden, Rachel M. (2007). "Warfarin
Anticoagulation in Hemodialysis Patients: A Systematic Review of Bleeding Rates".
570:"Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores"
346:
A score of ≥3 indicates "high risk", but does not necessarily mean that an anticoagulant cannot be given, as some risk factors may be modified.
445:
402:
893:
685:
Lip, Gregory Y.H. (2011). "Implications of the CHA2DS2-VASc and HAS-BLED Scores for
Thromboprophylaxis in Atrial Fibrillation".
920:
915:
44:(AF). It was developed in 2010 with data from 3,978 people in the Euro Heart Survey. Major bleeding is defined as being
757:
Popescu, B. A.; Reiner, Z.; Sechtem, U.; Sirnes, P. A.; Tendera, M.; Torbicki, A.; Vahanian, A.; et al. (2012).
930:
925:
264:
A calculated HAS-BLED score is between 0 and 9 and based on seven parameters with a weighted value of 0-2.
81:
461:
Apostolakis, Stavros; Lane, Deirdre A.; Guo, Yutao; Buller, Harry; Lip, Gregory Y. H. (28 August 2012).
45:
77:
41:
319:
889:
864:
829:
780:
738:
702:
667:
659:
607:
589:
550:
532:
492:
484:
441:
433:
384:
57:
883:
856:
819:
811:
770:
730:
694:
649:
639:
597:
581:
540:
524:
474:
410:
376:
211:
323:
49:
824:
799:
602:
569:
545:
512:
909:
335:
146:
141:
73:
121:
698:
644:
627:
528:
69:
37:
860:
775:
758:
734:
479:
462:
815:
663:
593:
536:
488:
585:
868:
833:
784:
742:
706:
671:
611:
554:
496:
388:
380:
268:
248:
Medication Usage
Predisposing to Bleeding: (Antiplatelet agents, NSAIDs)
191:
654:
171:
53:
149:: Cirrhosis or Bilirubin >2x Normal or AST/ALT/AP >3x Normal
68:
HAS-BLED is a medical tool used to calculate the one-year risk of
144:: Dialysis, transplant, Cr >2.26 mg/dL or >200 μmol/L
36:
is a scoring system developed to assess 1-year risk of major
885:
246: Prior Alcohol or Drug Usage History (≥ 8 drinks/week)
800:"Assessing bleeding risk in patients taking anticoagulants"
214:: (Unstable/high INR), Time in Therapeutic Range < 60%
440:. Oxford: Oxford University Press. pp. 201–203.
194:: Prior Major Bleeding or Predisposition to Bleeding
436:. In Kaski, Juan Carlos; Kjeldsen, Keld Per (eds.).
23:
18:
438:The ESC Handbook on Cardiovascular Pharmacotherapy
361:
359:
723:Journal of the American College of Cardiology
467:Journal of the American College of Cardiology
8:
823:
774:
653:
643:
601:
574:Journal of the American Heart Association
544:
478:
432:Dan, Gheorhe-Andre; Steffel, Jan (2019).
798:Shoeb, Marwa; Fang, Margaret C. (2013).
403:"HAS-BLED Score for Major Bleeding Risk"
124:: (uncontrolled, >160 mmHg systolic)
99:
355:
804:Journal of Thrombosis and Thrombolysis
15:
7:
40:in people taking anticoagulants for
849:American Journal of Kidney Diseases
14:
230: Elderly: Age > 65 years
687:The American Journal of Medicine
284:bnormal renal and liver function
1:
699:10.1016/j.amjmed.2010.05.007
529:10.1136/bmjopen-2017-017157
947:
861:10.1053/j.ajkd.2007.06.017
735:10.1016/j.jacc.2010.09.024
480:10.1016/j.jacc.2012.06.019
434:"4.1. Atrial fibrillation"
174:: Prior history of stroke
80:(AF). It is used with the
816:10.1007/s11239-013-0899-7
645:10.1093/eurheartj/ehaa612
888:. Springer. p. 20.
776:10.1093/eurheartj/ehs253
882:Kiser, Kathryn (2017).
586:10.1161/JAHA.118.009766
147:Abnormal liver function
142:Abnormal renal function
921:Medical scoring system
763:European Heart Journal
632:European Heart Journal
46:intracranial bleedings
27:risk of major bleeding
916:Diagnostic cardiology
381:10.1378/chest.10-0134
74:blood thinning drugs
56:> 2 g/dL, and/or
413:on 25 February 2021
78:atrial fibrillation
54:hemoglobin decrease
42:atrial fibrillation
318:A study comparing
931:Mnemonic acronyms
926:Medical mnemonics
447:978-0-19-875993-5
262:
261:
31:
30:
938:
900:
899:
879:
873:
872:
844:
838:
837:
827:
795:
789:
788:
778:
753:
747:
746:
717:
711:
710:
682:
676:
675:
657:
647:
622:
616:
615:
605:
565:
559:
558:
548:
507:
501:
500:
482:
458:
452:
451:
429:
423:
422:
420:
418:
409:. Archived from
399:
393:
392:
363:
100:
16:
946:
945:
941:
940:
939:
937:
936:
935:
906:
905:
904:
903:
896:
881:
880:
876:
846:
845:
841:
797:
796:
792:
769:(21): 2719–47.
755:
754:
750:
719:
718:
714:
684:
683:
679:
624:
623:
619:
580:(18): e009766.
567:
566:
562:
523:(12): e017157.
509:
508:
504:
460:
459:
455:
448:
431:
430:
426:
416:
414:
401:
400:
396:
375:(5): 1093–100.
365:
364:
357:
352:
344:
314:rugs or alcohol
258:
255:
254:
235:
219:
199:
179:
159:
156:
155:
129:
98:
89:
85:
66:
50:hospitalization
12:
11:
5:
944:
942:
934:
933:
928:
923:
918:
908:
907:
902:
901:
894:
874:
839:
790:
748:
712:
677:
638:(5): 373–498.
617:
560:
502:
473:(9): 861–867.
453:
446:
424:
394:
354:
353:
351:
348:
343:
340:
316:
315:
309:
303:
297:
291:
285:
279:
260:
259:
256:
252:
250:
244:
237:
236:
233:
231:
228:
221:
220:
217:
215:
208:
201:
200:
197:
195:
188:
181:
180:
177:
175:
168:
161:
160:
157:
153:
151:
138:
131:
130:
127:
125:
118:
110:
109:
106:
103:
97:
94:
87:
83:
72:for people on
70:major bleeding
65:
62:
29:
28:
25:
21:
20:
19:HAS-BLED score
13:
10:
9:
6:
4:
3:
2:
943:
932:
929:
927:
924:
922:
919:
917:
914:
913:
911:
897:
895:9783319546438
891:
887:
886:
878:
875:
870:
866:
862:
858:
855:(3): 433–40.
854:
850:
843:
840:
835:
831:
826:
821:
817:
813:
809:
805:
801:
794:
791:
786:
782:
777:
772:
768:
764:
760:
752:
749:
744:
740:
736:
732:
729:(2): 173–80.
728:
724:
716:
713:
708:
704:
700:
696:
692:
688:
681:
678:
673:
669:
665:
661:
656:
651:
646:
641:
637:
633:
629:
621:
618:
613:
609:
604:
599:
595:
591:
587:
583:
579:
575:
571:
564:
561:
556:
552:
547:
542:
538:
534:
530:
526:
522:
518:
514:
506:
503:
498:
494:
490:
486:
481:
476:
472:
468:
464:
457:
454:
449:
443:
439:
435:
428:
425:
412:
408:
404:
398:
395:
390:
386:
382:
378:
374:
370:
362:
360:
356:
349:
347:
341:
339:
337:
336:haemodialysis
331:
327:
325:
321:
313:
310:
307:
304:
301:
298:
295:
292:
289:
286:
283:
280:
277:
274:
273:
272:
270:
267:The HAS-BLED
265:
251:
249:
245:
243:
239:
238:
232:
229:
227:
223:
222:
216:
213:
210: Labile
209:
207:
203:
202:
196:
193:
189:
187:
183:
182:
176:
173:
169:
167:
163:
162:
152:
150:
148:
143:
139:
137:
133:
132:
126:
123:
119:
116:
112:
111:
107:
104:
102:
101:
95:
93:
91:
79:
75:
71:
63:
61:
59:
55:
51:
47:
43:
39:
35:
26:
22:
17:
884:
877:
852:
848:
842:
810:(3): 312–9.
807:
803:
793:
766:
762:
751:
726:
722:
715:
693:(2): 111–4.
690:
686:
680:
655:1887/3279676
635:
631:
620:
577:
573:
563:
520:
516:
505:
470:
466:
456:
437:
427:
415:. Retrieved
411:the original
406:
397:
372:
368:
345:
332:
328:
320:HEMORR2HAGES
317:
311:
305:
299:
293:
287:
281:
275:
271:stands for:
266:
263:
247:
241:
225:
205:
185:
165:
145:
135:
122:Hypertension
114:
67:
33:
32:
278:ypertension
90:-VASc score
58:transfusion
910:Categories
350:References
105:Condition
64:Definition
664:1522-9645
594:2047-9980
537:2044-6055
489:1558-3597
302:abile INR
869:17720522
834:23479259
785:22922413
743:21111555
707:20887966
672:32860505
612:30371183
555:29273652
517:BMJ Open
497:22858389
417:11 April
389:20299623
269:mnemonic
192:Bleeding
38:bleeding
34:HAS-BLED
825:3888359
603:6222935
546:5778339
296:leeding
117:
108:Points
24:Purpose
892:
867:
832:
822:
783:
741:
705:
670:
662:
610:
600:
592:
553:
543:
535:
495:
487:
444:
407:MDCalc
387:
308:lderly
240:
224:
204:
190:
184:
172:Stroke
170:
164:
140:
134:
120:
113:
369:Chest
342:Score
324:ATRIA
290:troke
890:ISBN
865:PMID
830:PMID
781:PMID
739:PMID
703:PMID
668:PMID
660:ISSN
608:PMID
590:ISSN
551:PMID
533:ISSN
493:PMID
485:ISSN
442:ISBN
419:2021
385:PMID
76:for
857:doi
820:PMC
812:doi
771:doi
731:doi
695:doi
691:124
650:hdl
640:doi
598:PMC
582:doi
541:PMC
525:doi
475:doi
377:doi
373:138
212:INR
96:Use
82:CHA
912::
863:.
853:50
851:.
828:.
818:.
808:35
806:.
802:.
779:.
767:33
765:.
761:.
737:.
727:57
725:.
701:.
689:.
666:.
658:.
648:.
636:42
634:.
630:.
606:.
596:.
588:.
576:.
572:.
549:.
539:.
531:.
519:.
515:.
491:.
483:.
471:60
469:.
465:.
405:.
383:.
371:.
358:^
338:.
322:,
92:.
86:DS
60:.
52:,
48:,
898:.
871:.
859::
836:.
814::
787:.
773::
745:.
733::
709:.
697::
674:.
652::
642::
614:.
584::
578:7
557:.
527::
521:7
499:.
477::
450:.
421:.
391:.
379::
312:D
306:E
300:L
294:B
288:S
282:A
276:H
257:1
253:1
242:D
234:1
226:E
218:1
206:L
198:1
186:B
178:1
166:S
158:1
154:1
136:A
128:1
115:H
88:2
84:2
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.